Hospital Variations in Time-To-Crisis-Resolution Among Children and Adolescents With Sickle Cell Disease
Document Type
Letter to the Editor
Publication Date
11-5-2025
Journal
American journal of hematology
DOI
10.1002/ajh.70129
Keywords
arginine; sickle cell disease; sickle cell disease treatment with arginine therapy (STArT); time‐to‐crisis‐resolution; vaso‐occlusive pain episodes
Abstract
Analysis of the placebo cohort in the STArT trial shows that patient characteristics and hospital site strongly influence time-to-crisis-resolution and total opioid use in children and young adults with sickle cell disease, highlighting the need to account for these factors in the design of future clinical trials.
APA Citation
Rees, Chris A.; Hatabah, Dunia; Korman, Rawan; Ahmad, Fahd; Airewele, Gladstone; Akinsola, Bolanle; Alzraikat, Noor; Bakshi, Nitya; Brousseau, David C.; Brown, Kathleen; Campbell, Andrew D.; Casper, T Charles; Chang, Todd P.; Chumpitazi, Corrie E.; Cohen, Daniel; Coleman, Keli D.; Cruz, Andrea T.; Denton, Christopher; Ellison, Angela; Fields, Melanie E.; Harding, Monica; Leibovich, Sara; Remiker, Allison; Singh, Nidhi V.; Thompson, Alexis A.; Vichinsky, Elliott; Villella, Anthony; Wynn, Bridget; Dampier, Carlton; and Morris, Claudia R., "Hospital Variations in Time-To-Crisis-Resolution Among Children and Adolescents With Sickle Cell Disease" (2025). GW Authored Works. Paper 8138.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/8138
Department
Pediatrics